Results 21 to 30 of about 53,817 (192)

Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. [PDF]

PLoS ONE, 2014
The effects of blocking the epidermal growth factor receptor (EGFR) in acute kidney injury (AKI) are controversial. Here we investigated the renoprotective effect of erlotinib, a selective tyrosine kinase inhibitor that can block EGFR activity, on ...
Yukihiro Wada, Masayuki Iyoda, Kei Matsumoto, Yuki Shindo-Hirai, Yoshihiro Kuno, Yasutaka Yamamoto, Taihei Suzuki, Tomohiro Saito, Ken Iseri, Takanori Shibata   +9 more
doaj   +1 more source

Successful retreatment with erlotinib after erlotinib-related interstitial lung disease

, 2021
Background: Epidermal growth factor receptor tyrosine kinase inhibitors are effectively being used in the treatment of non-small cell lung cancer. Although most of their adverse effects are mild to moderate, they occasionally can cause life-threatening ...
ADLI, MUSTAFA
core   +1 more source

Difluoromethylenation of Alkynes: Streamlined Access to Allyl Difluorides

Angewandte Chemie, EarlyView.
Stabilizing primary oxocarbenium in HF/pyridine unlocks a direct alkyne difluoromethylenation – an efficient route to synthetically‐relevant allyl difluorides in a single step. ABSTRACT A direct difluoromethylenation of alkynes has been developed using HF/pyridine as a dual acidic and fluorinating medium. The reaction proceeds via in situ generation of
Fabien Naullet, Sourav Mondal, Frédéric Guégan, Bastien Michelet, Sébastien Thibaudeau   +4 more
wiley   +2 more sources

Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

EJNMMI Research, 2018
Background Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer.
Dorra Amor, Sébastien Goutal, Solène Marie, Fabien Caillé, Martin Bauer, Oliver Langer, Sylvain Auvity, Nicolas Tournier   +7 more
doaj   +1 more source

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses

Hereditas, 2020
Background Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment.
Huyue Zhou, Qiumei Xiang, Changpeng Hu, Jing Zhang, Qian Zhang, Rong Zhang   +5 more
doaj   +1 more source

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Frontiers in Oncology, 2020
Background: Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability, but few evidences are available regarding its efficacy at reduced ...
Shen Zhao, Shen Zhao, Shen Zhao, Zhen Zhang, Zhen Zhang, Zhen Zhang, Zhen Zhang, Wenfeng Fang, Wenfeng Fang, Wenfeng Fang, Yaxiong Zhang, Yaxiong Zhang, Yaxiong Zhang, Zhonghan Zhang, Zhonghan Zhang, Zhonghan Zhang, Shaodong Hong, Shaodong Hong, Shaodong Hong, Yuxiang Ma, Yuxiang Ma, Yuxiang Ma, Ting Zhou, Ting Zhou, Ting Zhou, Yunpeng Yang, Yunpeng Yang, Yunpeng Yang, Yan Huang, Yan Huang, Yan Huang, Hongyun Zhao, Hongyun Zhao, Hongyun Zhao, Li Zhang, Li Zhang, Li Zhang   +36 more
doaj   +1 more source

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Frontiers in Pharmacology, 2022
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug ...
Xi-xi Hou, Xiao-qing Gong, Long-fei Mao, Ge Sun, Ge Sun, Jian-xue Yang, Jian-xue Yang   +6 more
doaj   +1 more source

Erlotinib-Induced Papulopustular Eruption and Mucositis

Southern Clinics of Istanbul Eurasia, 2018
Erlotinib is an epidermal growth factor inhibitor that is used in the treatment of advanced stage cancers. Cutaneous reactions to erlotinib use have been observed. A 70-year-old male patient presented with the complaint of a rash on his nose and a lesion
Zehra Aşiran Serdar, Ezgi Aktaş Karabay   +1 more
doaj   +1 more source

Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer

Chinese Medical Journal, 2020
. Background:. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are widely used to treat non-small cell lung cancer (NSCLC).
Peng-Fei Wu, Wei-Wei Gao, Cui-Lan Sun, Tai Ma, Ji-Qing Hao, Xiu-Yuan Hao   +5 more
doaj   +1 more source

Erlotinib-Guided Self-Assembled Trifunctional Click Nanotheranostics for Distinguishing Druggable Mutations and Synergistic Therapy of Nonsmall Cell Lung Cancer

, 2018
The outcome of molecular targeted therapies is restricted by the ambiguous molecular subtypes of nonsmall cell lung cancer (NSCLC), which are difficult to be defined with druggable mutations, and the inevitable emergence of drug-resistance.
Xiaodong Xie, Haijun Chen (580445), Yingying Zhang, Ziying Li, Huijuan Zhang (439573), Yingying Zhang (42910), Fengqiao Li, Yu Gao (69071), Huijuan Zhang, Lu Zhang, Tingting Lv, Ziying Li (2592430), Fengqiao Li (5870084), Yu Gao, Lu Zhang (50563), Lee Jia (409469), Tingting Lv (470075), Lee Jia, Xiaodong Xie (58260), Haijun Chen   +19 more
core   +1 more source